Shares of Evgen Pharma PLC (LON:EVG) fell 1.4% during trading on Friday . The stock traded as low as GBX 17.76 ($0.23) and last traded at GBX 17.76 ($0.23), 8,046 shares traded hands during trading. A decline of 96% from the average session volume of 207,445 shares. The stock had previously closed at GBX 18 ($0.24).
Separately, FinnCap restated a “corporate” rating on shares of Evgen Pharma in a report on Thursday, June 13th.
The company has a fifty day simple moving average of GBX 17.93. The firm has a market cap of $23.71 million and a P/E ratio of -6.62.
Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer.
Read More: Investing in Dividend Stocks
Receive News & Ratings for Evgen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evgen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.